Breast Cancer Res Treat (2007) 105:67–74 References 1. Brodie A, Jelovac D, Long BJ (2003) Predictions from a pre- clinical model: studies of aromatase inhibitors and antiestrogens. Clin Cancer Res 9:455S–459S 2. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Stafﬂer B, Chaudri-Ross HA, Dugan M (2001) Superior efﬁcacy of letrozole versus tamoxifen as ﬁrst-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596–2606 3. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A; Breast International Group (BIG) 1-98 Collaborative Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757 4. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists’ Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62 5. Coates AS, Keshaviah A, Thu¨rlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Gold- hirsch A (2007) Five years of letrozole compared with tamoxifen as adjuvant therapy for postmenopausal women with endocrine- responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486–492 6. International Breast Cancer Study Group. http://www.ibcsg.org 7. Anastrozole package insert. Wilmington, DE; AstraZeneca Pharmaceuticals, 2002 8. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerﬁeld MR (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619–629 9. National Comprehensive Cancer Network Practice Guidelines in Oncology. Breast Cancer Version 2.2006. Available at: http:// www.nccn.org/professionals/physician_gls/PDF/breast.pdf 10. Bhatnagar AS, Batzl C, Hausler A, Schieweck K, Lang M, Trunet PF (1996) Pharmacology of non-steroidal aromatase inhibitors. In: Pasqualini JR, Katzenellenbogen BS (eds) Hormone-depen- dent cancer. Marcel Dekker, New York, pp 155–168 11. Bhatnager AS, Brodie AMH, Long BJ, Evans DB, Miller WR (2001) Intracellular aromatase and its relevance to the pharma- cological efﬁcacy of aromatase inhibitors. J Steroid Biochem Mol Biol 76:199–202 12. Miller WR (1999) Biology of aromatase inhibitors: pharmacology/ endocrinology within the breast. Endocr Relat Cancer 6:187–195 13. Lu Q, Liu Y, Long BJ, Grigoryev D, Gimbel M, Brodie A (1999) The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat 57:183–192 14. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE (2002) Inﬂuence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer women evaluated in a randomized, cross-over study. J Clin Oncol 20:751–757 73 15. Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron D, Dowsett M (2006) Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 24(18S):15s. Abstract 552 16. Murray J, Young O, Renshaw L White S, Prescot RJ, Krause A, Evans DB, Salem R, Cameron D, Dowsett M, Miller WR, Dixon JM (2004) Letrozole and anastrozole: a pre-operative study of their effects on ER positive breast cancers in postmenopausal women. Presented at the 27th annual San Antonio breast cancer symposium, San Antonio, 8–11 December 2004. Abstract 406 17. Dowsett M, A’Hern R, Smith I; on behalf of the IMPACT Tri- alists (2005) Ki67 after 2 weeks endocrine treatment predicts relapse-free survival (RFS) in the IMPACT trial. Presented at the 28th Annual San Antonio Breast Cancer Symposium, 8–11 December 2005. Abstract 45 18. Rose C, Vtoraya O, Pluzanska A, Davidson N, Gershanovich M, Thomas R, Johnson S, Caicedo JJ, Gervasio H, Manikhas G, Ben Ayed F, Burdette-Radoux S, Chaudri-Ross HA, Lang R (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39:2318–2327 19. Houghton J, on behalf of the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) Trialists’ Group (2006) Initial adjuvant therapy with anastrozole (a) Reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (t). Ann Oncol 17(Suppl 9):ix94. Abstract 243PD 20. Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes J, Thuerlimann B, Paridaens R, Monnier A, Lang I, WardleyA, Nogaret JM, Gelber R, Castiglione-Gertsch M, Price K, Coates A, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A (2007) Predictors of early relapse in postmenopausal women with hor- mone receptor positive breast cancer in the BIG 1-98 trial. Ann Oncol 18:859–867 21. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T; ATAC Trialists’ Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adju- vant treatment of postmenopausal women with early breast cancer: ﬁrst results of the ATAC randomised trial. Lancet 359:2131–2139. Erratum in: Lancet 2002;360:1520 22. Buzdar AU, Guastalla JP, Nabholtz JM, Cuzick J (2006) Impact of chemotherapy regimens prior to endocrine therapy: results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer 107:472–480 23. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T; The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efﬁcacy and safety update analyses. Cancer 98:1802–1810 24. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL (2005) Randomized trial of letrozole fol- lowing tamoxifen as extended adjuvant therapy in receptor- positive breast cancer: updated ﬁndings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271 25. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, Panel members (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583 26. Itoh T, Karlsberg K, Kijima I, Yuan YC, Smith D, Ye J, Chen S (2005) Letrozole-, anastrozole-, and tamoxifen-responsive genes 123